For forty years I have dedicated my laboratory toward the study of acute and chronic kidney injury from both ischemic and nephrotoxic compounds.  We have helped to understand mechanisms, and develope therapeutics for many potential approaches of acute kidney injury. We have developed, patented and licensed non-toxic gentamicin congeners and RAP,  an inhibitor of proximal tubule endocytosis, that has the potential to minimize nephrotoxic uptake by proximal tubule cells.  We have also spent the last twenty years developing non-linear microscopy to quantify dynamic cellular and subcellular processes in vivo.  This led to our NIH-P30 Imaging Core O’Brien Center of Excellence beginning in 2002 as a P-50 and continuously renewed thru 2022 as a P-30.  This facilitated advancement of fluorescent technologies to study and quantify, mechanistic and therapeutic insights into disease processes in animal models.  We have developed unique rodent models allowing novel studies and mechanistic insights for the study of albumin filtration and proximal tubule endocytosis, processing and transcytosis.  These observations resulted in numerous publications and patents covering these quantitative approaches, and the development of a company, FAST BioMedical, to translate GFR and plasma volume technology to patients.  This approach is being used to answer complex questions with an emphasis on congestive heart failure and cardio-renal syndrome.